InvestorsHub Logo
Followers 154
Posts 2653
Boards Moderated 0
Alias Born 01/29/2004

Re: abew4me post# 277429

Tuesday, 10/20/2020 1:37:59 PM

Tuesday, October 20, 2020 1:37:59 PM

Post# of 464087
I doubt it. But...

Seriously...has other biotech companies scheduled a conference at a CTAD Alzheimer conference to release the results of their phase 2 trial from another disease unrelated to Alzheimers?


Good question. I doubt that it has happened.

The bigger question is, why, ever, would the people running this conference allow this to happen, to allow the revelation of detailed clinical results for a different, somewhat unrelated disease? How was this arranged, by whom, for what purpose?

Clearly, Anavex people had to approach the CTAD people and convince them that their presentation of the Parkinson's disease dementia results were both significant, and more importantly, applicable and useful for Alzheimer's researchers.

"Dr. Missling, thank you for your call, but we are the CLINICAL TRIALS ON ALZHEIMER'S DISEASE people. You will need to go to the Parkinson's people. We don't do Parkinson's stuff. Very different disease."

Dr. Missling, "But sir, take a look at these data. See how our drug really therapeutically nailed the dementia of Parkinson's. Blarcamesine can do that for Alzheimer's, too. Your people need to know about this, see the data."

The CTAD guy, "Whoa! Look at those metrics. Stat sig through and through. Yes, our people need to learn of this. It will be our honor to roll out these data for the whole world, for everybody dealing with CNS pathologies involving loss of cognition and consequent dementia."

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News